Invion Stock

Invion Net Change in Cash

The Net Change in Cash of Invion (IVX.AX) as of Sep 12, 2026 is 66,800.00 AUD. In the previous year, Net Change in Cash was -3.30 M AUD — a change of -102.02% (higher).

Net Change in Cash

66,800.00AUD

YoY

-102.02%

Last updated:

Net Change in Cash of Invion is 2026 66,800.00 AUD. Net Change in Cash of Invion was 2025 -3.30 M AUD. It decreases by -102.02% higher compared to the previous year.

The Invion Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
1.97 M AUD
Jan 1, 2019
-2.12 M AUD
Jan 1, 2020
-152,500.00 AUD
Jan 1, 2021
418,000.00 AUD
Jan 1, 2022
7.44 M AUD
Jan 1, 2023
-4.39 M AUD
Jan 1, 2024
-3.30 M AUD
Jan 1, 2025
66,800.00 AUD
The Invion Net Change in Cash history
YEARNet Change in CashYoY
66,800.00AUD-102.02%
-3.30 MAUD-24.77%
-4.39 MAUD-159.01%
7.44 MAUD+1,679.09%
418,000.00AUD-374.10%
-152,500.00AUD-92.81%
-2.12 MAUD-207.41%
1.97 MAUD+311.14%
480,100.00AUD-125.99%
-1.85 MAUD+10.74%
-1.67 MAUD-285.33%
900,000.00AUD
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Net Change in Cash of Invion is 66,800.00 AUD in 2026.

Net Change in Cash of Invion changed from -3.30 M AUD to 66,800.00 AUD, representing a -102.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Invion since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Invion historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Invion

All Key Metrics — Invion